Does Metformin Reduce Visceral Fat?

Does metformin get rid of visceral fat? This is a common question among people managing type 2 diabetes, PCOS, or insulin resistance. Metformin, a biguanide medicine widely prescribed in the UK, can modestly reduce visceral fat as a secondary effect of improving insulin sensitivity, but it is not licensed as a weight-management or fat-loss treatment. Understanding what the clinical evidence actually shows, who is most likely to benefit, and how lifestyle changes fit alongside medication is essential for setting realistic expectations and making informed decisions with your clinician.

Does metformin actually reduce visceral fat?

Metformin can modestly reduce visceral fat by improving insulin sensitivity, but this is a secondary effect rather than a primary mechanism, and it is not licensed in the UK for weight management or abdominal fat reduction.

Metformin can modestly reduce visceral fat in some people, but it is not primarily a fat-loss medicine and should not be thought of as a direct treatment for abdominal obesity. Metformin is a biguanide medicine licensed in the UK for the management of type 2 diabetes.^[1][19] Its use in polycystic ovary syndrome (PCOS) is off-label in the UK, though it is supported by NICE guidance on PCOS diagnosis and management.^[2][3] Its primary mechanism is to reduce hepatic glucose production and improve insulin sensitivity, which can indirectly influence fat distribution over time.^[4][5]

Visceral fat, the metabolically active fat stored around the abdominal organs, is closely linked to insulin resistance. Because metformin improves how the body responds to insulin, it may reduce the hormonal environment that encourages visceral fat accumulation. However, this effect is secondary to its glucose-lowering action rather than a direct fat-burning mechanism.

It is important to be clear that metformin is not licensed in the UK as a weight-management medicine. Any reduction in visceral fat observed during treatment is considered a beneficial secondary effect rather than a primary therapeutic goal. People who are considering treatment specifically for visceral fat or weight management should discuss the full range of available options with their GP or a qualified clinician, as other licensed treatments may be more appropriate for that purpose.

What does the clinical evidence say about metformin and belly fat?

Clinical studies, including the landmark Diabetes Prevention Program, show metformin produces small but real reductions in waist circumference and visceral fat, though lifestyle interventions consistently produce greater effects.

Clinical studies suggest that metformin produces modest reductions in visceral fat, particularly in people with insulin resistance, type 2 diabetes, or PCOS, though the effect size is generally smaller than that seen with lifestyle interventions alone. Systematic reviews and randomised controlled trials have found statistically significant reductions in waist circumference and, in some imaging studies, visceral adipose tissue in people taking metformin compared with placebo, but the absolute reductions are typically small.

A notable body of evidence comes from studies in people with PCOS, where metformin has been shown to reduce central adiposity alongside improvements in hormonal and metabolic markers. In people with type 2 diabetes, improvements in visceral fat have been observed alongside better glycaemic control, though it can be difficult to separate the effect of metformin from the effect of improved diet and activity that often accompanies diabetes management.

The landmark Diabetes Prevention Program (DPP) study, conducted in the United States and published in the New England Journal of Medicine (Knowler et al., 2002), found that metformin reduced the progression to type 2 diabetes and was associated with modest weight loss and reductions in waist circumference. The DPP's primary outcomes were weight and waist circumference rather than visceral adipose tissue measured by imaging, and the intensive lifestyle intervention arm produced significantly greater reductions in both measures. This evidence reinforces the view that metformin may support, but cannot replace, dietary and physical activity changes when the goal is reducing visceral fat. Overall, the evidence supports a real but limited effect, and expectations should be calibrated accordingly.

Who is most likely to see a reduction in visceral fat on metformin?

People with insulin resistance, type 2 diabetes, or PCOS are most likely to benefit, as metformin targets the hyperinsulinaemia that drives visceral fat accumulation in these groups.

People with insulin resistance, type 2 diabetes, or PCOS are most likely to experience a meaningful reduction in visceral fat while taking metformin. The medicine's mechanism of improving insulin sensitivity means that those whose visceral fat accumulation is driven by hyperinsulinaemia or insulin resistance stand to benefit most. In contrast, people with normal insulin sensitivity are less likely to see significant changes in fat distribution from metformin alone, based on the available evidence in metabolically at-risk populations.

Individuals with a higher baseline level of visceral fat and those who are overweight or living with obesity tend to show greater absolute reductions in abdominal adiposity in clinical studies, though this partly reflects the greater room for improvement in this group. Age, sex, and hormonal status also play a role: women with PCOS, for example, often show more pronounced improvements in central fat distribution alongside reductions in androgen levels. It should be noted that metformin use in PCOS is off-label in the UK and should be based on shared decision-making between the patient and their clinician, in line with NICE guidance on PCOS.

Genetic factors influencing metformin absorption and response, including variants in the SLC22A1 gene encoding the organic cation transporter OCT1, have been explored in pharmacogenomic research. However, this is an area of ongoing investigation and is not part of routine clinical testing or prescribing decisions in the UK at present.

For people who do not have diabetes or PCOS, metformin is not routinely prescribed in the UK for visceral fat reduction. A GP or specialist can assess whether metformin is appropriate based on an individual's metabolic profile, and can also discuss whether other licensed interventions, including newer medicines or structured weight-management programmes, might be better suited to their needs.

What else can you do alongside metformin to lose visceral fat?

Combining metformin with a calorie-controlled diet and at least 150 minutes of moderate aerobic activity per week, as recommended by UK Chief Medical Officers, produces the greatest reductions in visceral fat.

Lifestyle modification, particularly a combination of a calorie-controlled diet and regular physical activity, remains the most effective strategy for reducing visceral fat and should be pursued alongside any medicine, including metformin. NICE guidance on weight management emphasises that behavioural and dietary interventions form the foundation of treatment, with pharmacological options considered as adjuncts rather than replacements.

Aerobic exercise, such as brisk walking, cycling, or swimming, has strong evidence for reducing visceral fat independently of overall weight loss. Resistance training also contributes by improving insulin sensitivity and preserving lean muscle mass, which supports a healthier metabolic rate. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on at least two days per week.^[12][13] Evidence suggests that even modest increases in activity can meaningfully reduce visceral adiposity.

Dietary approaches that reduce refined carbohydrate and added sugar intake are particularly relevant for people with insulin resistance, as these foods drive postprandial insulin spikes that promote visceral fat storage. A Mediterranean-style diet, rich in vegetables, legumes, wholegrains, and unsaturated fats, has good evidence for reducing cardiometabolic risk and visceral fat over time.

For people who require additional pharmacological support beyond metformin, licensed weight-management medicines such as semaglutide (Wegovy) and tirzepatide (Mounjaro) have demonstrated significant reductions in body weight and visceral fat in clinical trials, as reflected in their UK marketing authorisations and SmPCs.^[15][16] Access to these medicines through the NHS can vary depending on local Integrated Care Board commissioning, and eligibility criteria apply. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a clinician can assess which approach, if any, is clinically appropriate for an individual's circumstances. Referral to a specialist weight-management service via a GP is also an option for those with complex needs.

Side effects and safety considerations for long-term metformin use

Metformin is generally well tolerated, but long-term use can cause vitamin B12 deficiency, and it is contraindicated in significant renal impairment (eGFR below 30 ml/min/1.73 m2) due to the risk of lactic acidosis.

Metformin is generally well tolerated and has a well-established long-term safety profile, making it one of the most widely prescribed medicines in the UK for type 2 diabetes. The most common side effects are gastrointestinal and include nausea, diarrhoea, abdominal discomfort, and a metallic taste in the mouth.^[19][1] These effects are most pronounced when starting treatment or increasing the dose, and they can often be minimised by taking metformin with or after food and by using a slow-release formulation where appropriate.

A clinically important but uncommon risk is vitamin B12 deficiency, which can develop with long-term use because metformin reduces B12 absorption in the gut. The MHRA Drug Safety Update (2020) advises that healthcare professionals should consider testing B12 levels periodically in people on long-term metformin, particularly those who are symptomatic (for example, fatigue, peripheral tingling, or cognitive changes) or who have other risk factors for deficiency. Supplementation is straightforward if deficiency is identified.

Lactic acidosis is a rare but serious complication associated with metformin, most commonly in people with significant renal impairment, severe hepatic disease, or acute illness causing dehydration or haemodynamic instability.^[27][28] In line with the metformin SmPC, the medicine is contraindicated when eGFR is below 30 ml/min/1.73 m2, should not be initiated if eGFR is below 45 ml/min/1.73 m2, and requires dose review and closer monitoring when eGFR falls below 45 ml/min/1.73 m2 in those already established on treatment. Renal function should be checked before starting and monitored regularly during treatment. Excessive alcohol intake should be avoided, as it increases the risk of lactic acidosis.^[25][26]

During acute illness involving dehydration, severe infection, or reduced tissue oxygenation, metformin should be temporarily stopped until recovery, in line with standard sick-day guidance. Patients should be advised to seek prompt medical advice if they become acutely unwell while taking metformin.

Metformin should be used with caution around procedures involving iodinated contrast media, and temporary discontinuation is often advised in line with the SmPC and local radiology protocols.^[24] Women of childbearing potential should discuss contraception and pregnancy planning with their prescriber, as the safety profile in pregnancy requires individual assessment. Any suspected adverse effects should be reported to a GP, and healthcare professionals and patients can report suspected side effects to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions